Melatonin Levels Decrease in the Umbilical Cord in Case of Intrauterine Growth Restriction

Andrii Mykolaiovych Berbets¹*, Adrian Mykhailovych Barbe¹, Oksana Anatoliivna Andriiets¹, Anatolii Volodymyrovych Andriiets¹, Oleksandr Mykhailovych Yuzko¹

1. Department of Obstetrics and Gynecology, Bukovinian State Medical University, Chernivtsi, Ukraine

* Corresponding Author:
Andrii Mykolaiovych Berbets, PhD Student
2, Teatralna Sq, Chernivtsi, Ukraine, 58000.
Phone: +380501714679
E-mail: andriy.berbets@gmail.com

Received: July 26th, 2020 – Accepted: October 13th, 2020

Abstract

Intrauterine growth restriction (IUGR) is a common reason for perinatal morbidity and mortality. Also, it is often complicated with fetal distress. Melatonin is widely known as an anti-oxidant agent, and it might decrease the damage of tissues caused by hypoxia. It is also known that levels of pro- and anti-inflammatory cytokines are changed during pregnancy. Placental growth factor (PIGF) is responsible for the angiogenesis in the placenta. We aimed to investigate whether the level of melatonin, cytokines, and PIGF in umbilical blood after birth is different in the case of IUGR compared to normal fetuses. Fourteen women whose pregnancies were complicated with IUGR were included in the study group. The presence of IUGR was confirmed by ultrasound fetometry in the third pregnancy trimester, 30-36 weeks of gestation. All patients delivered their children vaginally after 37 weeks of pregnancy. The cases of severe fetal distress that required a caesarian section, obstetrical forceps, or vacuum extraction of the fetus were excluded from the study. We found that the concentrations of cytokines did not differ significantly between the groups. Also, no significant difference in the daytime of delivery was found between the groups. The concentrations of melatonin and PIGF in the umbilical blood at labor were significantly lowered in the case of IUGR compared to normal pregnancies. This fact, as we consider, is caused by altered production of melatonin and PIGF by the placenta. Therefore, the protective action of these two factors for the fetus at labor is decreased in IUGR.

Keywords: Pregnancy, placenta, IUGR, melatonin, cytokines, PIGF.

Abbreviations: ELISA – enzyme-linked immunosorbent assay; FLT-1 – fms-related tyrosine kinase-1; IL-1-β – interleukine-1-β; IL-4 – interleukine-4; IL-6 – interleukine – 6; IL-10 – interleukine-10; IUGR – intrauterine growth restriction; PI – placental insufficiency; PIGF – placental growth factor; sFLT-1 – soluble fms-like tyrosine kinase-1; TNF-α – tumor necrotizing factor-α; VEGFR – vascular endothelial growth factor receptor.

Introduction

The neuroendocrine system of a pregnant woman plays a crucial role in the successful development of pregnancy. The pineal gland (epiphysis) is one of the most important parts of this system. It produces and secretes such hormones as melatonin and serotonin. Melatonin (5-methoxy-N-acetyltryptamine) chemically belongs to the class of indols, and it easily crosses the blood-brain barrier [1, 2]. The placental melatonin system is present throughout pregnancy and regulates villous trophoblast differentiation [3]; melatonin is involved in successful implantation of a fertilized egg [3], influences the act of delivery [4], decreases oxidative stress in pregnancy [5], especially in case of pre-eclampsia [2, 6, 7]. In our previous studies, we established that melatonin decreases in pregnant women’s blood with intrauterine fetal growth restriction (IUGR) [8]. The interactions between the pineal gland and a placental trophoblast as between the producers of melatonin are still unclear. But it has been admitted that melatonin can be considered as one of the biochemical markers which depict the conditions of the placenta/placenta’s tissue.

Placental Growth Factor (PIGF), among others, can also be considered as such a marker. PIGF has a pro-angiogenic effect on the placental tissue; it also stimulates the proliferation of the trophoblast, and it has been known as a predictor and a diagnostic marker of pre-eclampsia [9, 10]. On the other hand, lately, this molecule attracts the attention of researchers in the case of placental insufficiency (PI) or fetal distress. In our recent study [11], we established that concentrations of PIGF in the blood of pregnant women significantly decrease in case of placental insufficiency, manifested as intrauterine fetal growth restriction syndrome. Other studies confirm the fact that the levels of PIGF are lowered in case the hypoxic conditions of a
fetus and/or a newborn are eventually diagnosed [12], or if blood flow disorders, expressed as “ischemic placental syndrome”, are present in the uterine and umbilical arteries [13]. The presence of links between the decrease of PI GF and the expression of PI and IUGR has also been confirmed by other studies [14-16].

The impact of melatonin on the immune system, especially on the cytokine level, is being widely studied nowadays. Melatonin decreases stress-induced inflammation [17] and reduces the inflammatory response in the case of sepsis due to a decrease in the level of interleukin-10 (IL-10) [18]. We also recently found that in the case of IUGR, melatonin concentrations in maternal blood significantly decrease, resulting in strengthening of the pro-inflammatory immunity, shown by the increasing of TNF-α, IL-1-β and IL-6 levels in the blood of pregnant women. The increase in the levels of the anti-inflammatory cytokines, such as IL-4 and IL-10, was also significant in the case of IUGR [8].

Based on the above-mentioned facts, the primary conclusion that can be drawn is that the changed levels of melatonin, PlGF, and cytokines both in the blood plasma of a pregnant woman and umbilical blood might be relevant in the diagnosis of PI and IUGR.

Material and Methods

Subjects

The study was conducted on 14 women whose pregnancies were complicated with IUGR. The presence of IUGR was confirmed by ultrasound fetometry in the third pregnancy trimester, at 36 weeks of gestation (the estimated bodyweight of the fetus was below the third percentile for the current pregnancy term). The control group consisted of 13 women who had uncomplicated pregnancies. All patients delivered their children vaginally after 37 weeks of pregnancy. The cases of severe fetal distress, which required a caesarian section, obstetrical forceps, or vacuum extraction of the fetus, were excluded from the study. All the cases of IUGR were confirmed after the birth of fetuses. The umbilical blood was taken immediately after a baby’s birth from the placental side of the clamped and cut umbilical cord before the birth of the placenta.

Proceeding of biochemical analysis

The concentrations of melatonin and PlGF were assayed using an ELISA kit manufactured by “IB” (Germany); the concentrations of pro-inflammatory (TNF-α, IL-1-β, IL-6) and anti-inflammatory (IL-4, IL-10) cytokines were measured using diagnostic kits manufactured by “Vector Best” (Ukraine).

Statistical analysis

Statistical data were calculated using the MedCalc software, developed by “MedCalc Software” (Ostend, Belgium). The results were estimated using the Mann-Whitney U-test for small groups. A P-value <0.05 was considered statistically significant.

Ethics approval

The study was approved by the Biological and Medical Ethics Committee of the Higher State Educational Establishment of Ukraine “Bukovinian State Medical University” (minutes No3, March 30th, 2017), and was carried out following The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. All the patients involved in the study gave their consent for participation and publication of the study’s results.

Results

The levels of melatonin in the umbilical blood taken from the patients from the studied groups are represented in Table 1.

As can be seen in Table 1, the level of melatonin in the umbilical blood, taken after a newborn’s birth from the placental side of the umbilical cord before the birth of the placenta, was significantly lower (P=0.0101) compared to healthy women (Figure 1). Therefore, we can affirm that in the case of IUGR, the levels of melatonin in fetal blood are decreased at birth.

The levels of PlGF in the umbilical blood taken from the patients in the studied groups are represented in Table 2.

It has been established that the concentration of PlGF in the umbilical blood taken during labor from women whose pregnancies were complicated with IUGR was 1.57 times lower than women who had uncomplicated pregnancies, p<0.05 (Figure 2).

The levels of pro-inflammatory cytokines taken from the umbilical blood during labor from the examined patients are represented in Table 3.

Table 1: The levels of melatonin in the umbilical blood taken during labor from women with diagnosed IUGR.

|                | Women with IUGR (n=14) | Women of control group (n=13) | P-value |
|----------------|------------------------|------------------------------|---------|
| Melatonin (pg/ml) | 7.50 (3.0818 – 13.4042) | 14.60 (9.58 – 23.79)         | 0.00101 |

1. P-value was calculated accordingly to the Mann-Whitney U-test.
2. A 95% confidence interval of the median is indicated in brackets.
Table 2: The levels of PIGF in the umbilical blood taken during labor from women with diagnosed IUGR.

|                | Women with IUGR (n=14) | Women of control group (n=13) | P-value |
|----------------|-------------------------|------------------------------|---------|
| PIGF (pg/ml)   | 99.15*                  | 155.30                       | 0.0427  |
| (84.38 – 153.92) | (98.78 – 354.21)        |                              |         |

1. P-value was calculated accordingly to the Mann-Whitney U-test.
2. A 95% confidence interval of the median is indicated in brackets.

Figure 2: Graphical comparison of PIGF concentrations in the umbilical blood, taken after a newborn’s birth from the placental side of the umbilical cord before the placenta’s birth: study group (PIGF IUGR) and control group (PIGF control).

Table 3: The levels of TNF-α, IL-1-β, IL-6 in the umbilical blood taken during labor from women with diagnosed IUGR.

|                | Women with IUGR (n=14) | Women of control group (n=13) | P-value |
|----------------|-------------------------|------------------------------|---------|
| TNF-α (pg/ml)  | 28.55                   | 40.30                        | 0.1694  |
| (9.77 – 13.40) | (28.49 – 68.80)         |                              |         |
| IL-1-β (pg/ml) | 25.75                   | 38.00                        | 0.1821  |
| (18.94 – 37.32)| (22.80 – 56.24)         |                              |         |
| IL-6 (pg/ml)   | 38.60                   | 37.20                        | 0.7564  |
| (30.17 – 50.04)| (30.97 – 61.40)         |                              |         |

1. P-value was calculated accordingly to the Mann-Whitney U-test.
2. A 95% confidence interval of the median is indicated in brackets.
Data represented in Table 3 shows that there was no clear difference in the concentrations of pro-inflammatory cytokines between the studied groups. In the IUGR group, we found just a tendency of decrease of TNF-α and IL-1-β compared to patients with uncomplicated pregnancies, and IL-6 levels were practically equal in both groups.

The results of studying the levels of anti-inflammatory cytokines in the umbilical blood sampled during labor from women in the studied groups are represented in Table 4. Based on the data represented in Table 4, we can assert that no significant difference was found in the concentrations of anti-inflammatory cytokines between the studied groups.

Analysis of correlation links between studied indexes showed a moderate correlation between IL-1-β and TNF-α in the group of women who had uncomplicated pregnancies (r= 0.5738, P=0.0403, Figure 3).

We also established a moderate negative correlation link between the concentrations of anti-inflammatory cytokine IL-4 and melatonin in the group of patients with uncomplicated pregnancies (r= -0.6587, P=0.0143, Figure 4).

In the group of patients whose pregnancies were complicated with IUGR, we established a moderate correlation link between melatonin and pro-inflammatory cytokine IL-1-β levels (r= 0.6565, P=0.0108, Figure 5).

### Discussion

In our study, we found that the level of melatonin in the umbilical blood taken during the third period of labor from pregnant women whose pregnancies were complicated with IUGR is considerably decreased compared to the patients with uncomplicated pregnancies. Therefore, the level of melatonin in the fetal blood at labor is significantly lowered in the case of IUGR. It has been established that the placenta actively produces melatonin [3]. Production of melatonin significantly decreases in case of placental insufficiency, which manifests as IUGR [8], and the pineal glands of both mother and fetus seem to be unable to compensate for the deficiency of melatonin, which appears in case of PI.

Secondly, PIGF is also decreased in umbilical blood in case if the pregnancy is complicated with IUGR. There are papers that mention changes in the concentrations of PIGF in maternal blood, mostly in the case of pre-eclampsia [9-12]. Very few papers pay attention to the changes in the levels of PIGF in the case of IUGR, especially in the umbilical blood [14]. PIGF is responsible for angiogenesis in the placenta and actively binds to the vascular endothelial growth factor-1 receptor-1 (VEGFR-1), also known as fms-related tyrosine kinase-1 (FLT-1) and its soluble variant, soluble fms-like tyrosine kinase-1 (sFLT-1). Stimulation of FLT-1 causes angiogenesis and collateral growth in ischemic tissues [15]. Therefore, this process is violated in the case of PI, which manifests as IUGR.

Despite not finding the statistically significant difference between the umbilical cord concentrations of the studied cytokines in the groups (probably due to the small number of patients involved), we established that melatonin has a moderate correlation with one of the main pro-inflammatory cytokines, namely IL-1-β, if the pregnancy is complicated with IUGR. In the control group, this

### Table 4: The levels of IL-4 and IL-10 in the umbilical blood taken during labor from women with diagnosed IUGR.

|          | Women with IUGR (n=14) | Women of control group (n=13) | P-value |
|----------|------------------------|------------------------------|---------|
| IL-4 (pg/ml) | 7.45 (4.30 – 14.19) | 6.30 (3.30 – 8.65) | 0.3440 |
| IL-10 (pg/ml) | 2.10 (0.98 – 6.26) | 1.70 (0.00 – 2.95) | 0.3181 |

1. P-value was calculated accordingly to the Mann-Whitney U-test.
2. A 95% confidence interval of the median is indicated in brackets.

![Figure 3: Scatter diagram of data distribution and correlation graph between the concentrations of IL-1-β and TNF-α in the umbilical blood during labor in women who had uncomplicated pregnancies.](image)
correlation was also moderate but negative. Based on this fact, we suggest that melatonin plays the role of a moderator in the inflammatory reaction of the placental tissue, which is clearly expressed in the case of PI, manifesting as IUGR [8]. Anti-inflammatory and anti-oxidative actions of melatonin are widely known [5, 6], and they cannot be well enough expressed in the case of IUGR.

Our study has certain strengths, such as the strict inclusion criteria (the diagnosis of IUGR was confirmed in all cases included in the study group), sampling of the umbilical cord was performed during the third period of labor, immediately after the birth of the fetus (this non-invasive procedure allowed us to judge about the concentrations of the studied biochemical markers in the fetal blood at birth) and estimation of correlation links between studied indexes. However, it was also limited by the small number of patients included in the study.

Conclusion

The concentrations of melatonin and PlGF in the umbilical blood during labor are significantly lower in the case of IUGR compared to normal pregnancies. This fact, as we consider, is caused by the altered production of melatonin and PlGF by the placenta. Therefore, the protective action of these two factors for the fetus during labor is decreased in the case of IUGR.

Conflict of Interest

The authors declare that there is no conflict of interest.

References

1. Grishchenko VI. Rol' epifiza v fiziologii i patologii zhenskoy polovoy sistemy [Role of a pineal gland in physiology and pathology of woman’s reproductive system]. Khar’kov: Vishcha shkola; 1979. 248 s. (in Russian).
2. Shimada M, Seki H, Samejima M, Hayase M, Shirai F. Salivary melatonin levels and sleep-wake rhythms in pregnant women with hypertensive and glucose metabolic disorders: A prospective analysis. BioSci Trends. 2016;10(1):34-41. doi: 10.5582/bst.2015.01123
3. Soliman A, Lacasse A, Lanoix D, Sagrillo-Fagundes L, Boulard V, Vaillancourt C. Placental melatonin system is present throughout pregnancy and regulates villous trophoblast differentiation. J Pineal Res. 2015;59(1):38-46. doi: 10.1111/jpi.12236
4. Takayama H, Nakamura Y, Tamura H. Pineal gland (melatonin) affects the parturition time but not luteal function and fetal growth, in pregnant rats. Endoor J. 2003;50(1):37-43. doi: 10.1507/endo crj.50.37

5. Richter HG, Hansell JA, Raut Sh, Giussani DA. Melatonin improves placental efficiency and birth weight and increases the placental expression of antioxidant enzymes in undernourished pregnancy. J Pineal Res. 2009;46:357-364. doi: 10.1111/j.1600-079X.2009.0671.x

6. Reiter RJ, Dun Xian Tan, Korkmaz A, Rosales-Coral SA. Melatonin and stable circadian rhythms optimize maternal, placental and fetal physiology. Hum Reprod Update. 2013;20(2):293-307. doi: 10.1093/humupd/dmt054

7. Marseglia L, D'Angelo G, Manti S, Reiter RJ, Gitto E. Potential Utility of melatonin in preeclampsia, intrauterine fetal growth retardation, and perinatal asphyxia. Reprod Sci. 2016;23(8):970-977. doi: 10.1177/1933719115612132

8. Berbets A, Koval H, Barbe A, Albota O, Yuzko O. Melatonin decreases and cytokines increase in women with placental insufficiency [published online ahead of print, 2019 Apr 25]. J Matern Fetal Neonatal Med. 2019;1-6. doi:10.1080/14767058.2019.1608432

9. Bentona S, McCowan L, Heazell A. et al. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta. 2016 Jun;42:1-8. doi: 10.1016/j.placenta.2016.03.010. Epub 2016 Mar 23.

10. Ong C, Liao A, Cacho A et al. First-trimester maternal serum levels of placenta growth factor as predictor preeclampsia and fetal growth restriction. Am. J. Obstet. Gynecol. 98 (4) (2001) 608-611. doi: 10.1016/s0002-7844(01)01528-9.

11. Berbets A, Konkov D, Bulavenko O, Taran O, Bakun O. Melatonin, placental growth factor and placental hormones at placental insufficiency. Cell and Organ Transplantology. 2019; 7(2):103-107. doi:10.22494/cot.v7i2.100

12. Bligh LN, Greer RM, Kumar S. The relationship between maternal placental growth factor levels and intrapartum fetal compromise. Placenta. 2016 Dec;48:63-67. doi: 10.1016/j.placenta.2016.10.007.

13. Kwiatkowski S, Kwiatkowska E, Rzepka R, Dolegowksa B, Torbe A, Bartosik-Slawinska A. Using Doppler ultrasound of the uterine and umbilical arteries and disordered angiogenesis markers (sFlt-1/PlGF) in unified monitoring of ischemic placental syndrome patients. Hypertens Pregnancy. 2016 Nov;35(4):490-498. Epub 2016 Jun 17. doi: 10.1080/10641955.2016.1166688.

14. Broere-Brown ZA, Schalekamp-Timmermans S, Jaddoe VWW, Steegers EAP. Fetal Growth and Placental Growth Factor Umbilical Cord Blood Levels. Fetal Diagn Ther. 2018;43(1):26-33. doi: 10.1159/000475547.

15. Luttun A, Tja M, Carmellet P. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci. 2002;979:80-93. doi:10.1111/j.1749-6632.2002.tb04870.x

16. Sherrell H, Dunn L, Clifton V, Kumar S. Systematic review of maternal Placental Growth Factor levels in late pregnancy as a predictor of adverse intrapartum and perinatal outcomes. Eur J Obstet Gynecol Reprod Biol. 2018 Jun;225:26-34. doi: 10.1016/j.ejogrb.2018.03.059.

17. Woo-Jin Yi, Tae Sung Kim. Melatonin protects mice against stress-induced inflammation through enhancement of M2 macrophage polarization. Int Immunopharmacol. 2017;48: 146-158. doi: 10.1016/j.intimp.2017.05.006.

18. Mayo JC, Sainz RM, Tan DX, Harerdland R, Leon J, Rodriguez C, Reiter RJ. Antiinflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macro-phages. J Neuroimmunol. 2005;165: 139-49. doi: 10.1016/j.jneuroim.2005.05.002.

19. Najafi M, Shirazi A, Motevasseli E. Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacol. 2017;25(4):403-413. doi:10.1007/s10787-017-0332-5.

20. Esroy OF, Özkan N, Özsoy Z. Effects of melatonin on cytokine release and healing of colonic anastomoses in an experimental sepsis model. Ulus Travma Acil Cerrahi Derg. 2016;22(4): 315-321. doi: 10.5505/ijtes.2015.49465.